Tarsus Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Tarsus Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.
Tarsus Pharmaceuticals has raised $376M across 4 funding rounds on record, the most recent an undisclosed round of $125M announced in Mar 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Tarsus Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Mar 2025.
Tarsus Pharmaceuticals Funding Rounds
Tarsus Pharmaceuticals raised $75.6M in a Post-IPO Equity announced in May 2022.
1.3 years later, an undisclosed round of $100M was announced in Aug 2023.
8 months later, an undisclosed round of $75.0M was announced in Apr 2024.
11 months later, an undisclosed round of $125M was announced in Mar 2025.
Tarsus Pharmaceuticals Founders and Leadership Team
Contact details for the Tarsus Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Tarsus Pharmaceuticals Funding Compared to Other Biotechnology Startups
Tarsus Pharmaceuticals' latest round of $125M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Tarsus Pharmaceuticals in Biotechnology and Irvine
Companies Similar to Tarsus Pharmaceuticals
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Tarsus Pharmaceuticals Funding FAQs
What does Tarsus Pharmaceuticals do?
Tarsus Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.
How much funding has Tarsus Pharmaceuticals raised?
Tarsus Pharmaceuticals has raised $376M across 4 rounds on record. The most recent is an undisclosed round of $125M announced in Mar 2025.
When did Tarsus Pharmaceuticals last raise funding?
Tarsus Pharmaceuticals' most recent funding round on record is an undisclosed round of $125M, announced in Mar 2025.
Who founded Tarsus Pharmaceuticals?
FundedIQ lists Bobak Azamian (Founder) at Tarsus Pharmaceuticals.
Where is Tarsus Pharmaceuticals headquartered?
Tarsus Pharmaceuticals is based in Irvine, California, United States.
How many employees does Tarsus Pharmaceuticals have?
Tarsus Pharmaceuticals is in the 101-250 employee band.
How does Tarsus Pharmaceuticals' funding compare to other Biotechnology startups?
Tarsus Pharmaceuticals' latest round of $125M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Tarsus Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Tarsus Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.